Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
28 June 2021 | Story Lunga Luthuli | Photo Lunga Luthuli
South Campus: Social Responsibility Project team with Free State Department of Health nurses during the lunch of the campus’ COVID-19 pop-up vaccination site.

On Monday 27 September 2021, the University of the Free State, Provincial Department of Health and Department of Education launched a pop-up vaccination site at the South Campus bringing much-needed services closer to communities in the fight to end the COVID-19 pandemic.

Thandeka Mosholi, Head of Social Responsibility, Enterprise and Community Engagement, South Campus says, “We are next to the Mangaung community and bringing these services we encourage not only UFS staff and students but the surrounding communities to vaccinate for COVID-19. The institution and stakeholders are saying it is everyone’s responsibility for their health.”

She says, “If vaccination is recommended and we are told that it is safe, we encourage everyone including the youth to preserve our health and vaccinate.”

Representing the Department of Health, Papi Mokhele, Professional Pharmacist, says, “The initiative is aimed at reaching out to as many people to be vaccinated.”

He says, “At the moment the facility administers only the Pfizer vaccination and, as recommended by the National Government, we want to reach herd immunity – about 70% of the population – so that businesses, sporting facilities and many others can open and get our life back to normal.”

Other facilities the Department of Health has recently opened include the SABC Hoffman Square, Majakathata Taxi Rank, MUCCPP Health Centre in Phelindaba, Puma Garage in Bergman and Mangaung Outdoor Centre.

On partnering with the UFS, Mokhele says, “The COVID-19 vaccines have been put through clinical processes and quality assurance tests. They have also been approved by the South African Medicine Control Council and we call on the UFS community, especially students, to register and vaccinate.”

Coretha van den Heever, Teacher Trainer in the Social Responsibility Project, was recently vaccinated for the pandemic and says, “Let us protect ourselves and other people and not be the spreaders of the virus.”

She says, “People must make use of the facility; the UFS and government have brought the solution closer so that communities will not have to spend a lot of money travelling to get help.”

The vaccination centre will operate from Monday to Friday from 9:00 to 16:00.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept